European patients had to pay about $3.87 billion more for medicines in 2000-2007 because drugmakers stalled the sale of cheaper generic versions, EU antitrust regulators said.
More: continued here
European patients had to pay about $3.87 billion more for medicines in 2000-2007 because drugmakers stalled the sale of cheaper generic versions, EU antitrust regulators said.
More: continued here